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Abstract
Glioblastoma Multiforme (GBM) is the most aggressive and malignant form of primary
brain tumor. In many tumors, increased intracellular pH (pHi) is a hallmark of
aggressiveness. This increased pHi has been shown to be related to cell proliferation and
evasion of apoptosis as well as resistance to chemotherapy. As such, monitoring pHi and
the tumor pHi response to pharmacologic challenge, may aid in treatment planning and
patient management for this deadly cancer. A magnetic resonance imaging (MRI) method
called Chemical Exchange Saturation Transfer (CEST) has been used to detect changes in
pHi. Our group has recently developed a CEST technique called amine and amide
concentration independent detection (AACID), which was shown to be sensitive to pHi
changes induced by the anticancer drug, lonidamine (LND). However, LND is not
currently approved for use in humans. Our objective was to demonstrate that topiramate
(TPM), an antiepileptic drug that is well tolerated in humans, could also induce tumor
acidification. The goal this thesis was to quantify the changes in pHi induced by a single
dose of TPM in a mouse model of brain tumor. CEST spectra were acquired using a 9.4T
MRI scanner, before and 75 minutes after administration of TPM (dose: 120 mg/kg). A
significant increase in the AACID CEST effect was observed within brain tumors with no
change observed in contralateral tissue. The increase in AACID CEST corresponds to
tumor acidification as expected. Therefore TPM induced a rapid measurable metabolic
change in tumors that could provide valuable insight into cancer aggressiveness and aid
in tumor detection.
Keywords: MRI- Magnetic Resonance Imaging, CEST- Chemical Exchange Saturation
Transfer, pHi-Intracellular pH, APT- Amide Proton Transfer, TPM- Topiramate, AACIDAmine and Amide Concentration Independent Detection, GBM- Glioblastoma
Multiforme
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Chapter 1
1 Brain Tumors
1.1 Introduction
The work presented in this thesis uses high field magnetic resonance imaging (MRI) and
a novel chemical exchange saturation (CEST) method called amine and amide
concentration independent detection (AACID) for the quantification of changes in
intracellular pH (pHi) caused by a single dose of the anticonvulsant drug topiramate.
This introductory chapter provides a framework for understanding the motivation,
impact, and research methods presented in the subsequent chapters. Three principal
subjects are described. The first is a description of cancer metabolism, and the cellular
and chemical changes required to maintain the permissive microenvironment for disease
progression. The second is a description of the methods, particularly MRI, used for
disease diagnosis and treatment. Finally, the third is a description of the pH modulating
mechanisms affected by the drug used in this thesis.
1.2 Impact
Cancer ranks third among the most costly diseases. The most recent estimated cost of
cancer care in Canada in 2000 was $17.4 billion (www. omainsurance.com) [1]. Brain
cancer is an abnormal growth of cells in the brain and is commonly called a brain tumor.
There are two main types of brain tumors: primary and secondary. Primary brain tumors
develop from the various cells of the brain whereas secondary brain tumors develop from
a cancer that originates somewhere else in the body and then spreads to the brain.
Primary brain tumors are rare. For example, primary gliomas of the central nervous
system (CNS) account for < 2% of cancers. However, brain tumors are devastating to the
patient. Everyday 27 new patients are diagnosed with a brain tumor in Canada and it is
estimated that approximately 55,000 Canadians are living with brain tumors today
(braintumour.ca). In Canada, brain tumors represent the leading cause of death among
children under the age of 20 and are the major cause of death in young adults.

2

Approximately 20,000 new cases are diagnosed each year in the United States alone
[2,3]. The World Health Organization (WHO) has described 120 types of brain and
central nervous system (CNS) tumors (National Brain Tumor Society). Depending on
their origin and characteristics, the WHO classifies brain tumors from least aggressive to
most aggressive. Gliomas are the most aggressive (malignant) of CNS tumors arising
from glial cells or their precursors [4,5]. The WHO further classifies gliomas into grade IIV, with I being the least malignant and IV being the most malignant. Glioblastoma
Multiforme (GBM) is a WHO grade IV glioma [5,6] and is the most common primary
CNS tumor (abta.org) in European countries [7,8]. As glioblastomas are generally located
in the cerebral hemispheres, they may adversely affect the control center for speech,
motion, reading, writing, and executive function, thereby decreasing quality of life.
1.3 Disease Pathology and symptoms
Glioblastoma is characterized by the presence of hypoxic regions, high proliferation of
tumor cells, necrosis, and extensive angiogenesis (formation of new blood vessels from
existing ones). Hypoxic regions in the tumor occur due to inadequate development of
vasculature [9]. Proliferation is governed by genetic mutation and multiple cell signaling
pathways that control the expression of growth factors. The glioblastomas that occur in
younger patients have shown gene mutations that are different from the gene mutations in
glioblastomas that occur in elderly patients [10]. Glioblastomas that occurs in younger
patients may have altered or deleted p53. The p53 gene is also known as tumor protein 53
(Tp53), and encodes a protein that regulates the cell cycle [10]. In contrast, glioblastomas
in elderly patients have shown mutations in the phosphatase and tensin homolog (PTEN)
gene that is required for the production of the PTEN protein [11]. This protein regulates
the cell cycle and is responsible for keeping cells from growing and dividing in an
uncontrolled way. It also triggers cell self-destruction and is involved in the process of
cell movement (migration) and the formation of new blood vessels (angiogenesis).
Glioblastomas are also known to contain a high level of microRNA-21 (miR-21); an
antiapoptopic small RNA molecule [12]. They also contain a low level of microRNA-7
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(miR-7), an inhibitor of the epidermal growth factor receptor (EGFR) [13,14]. EGFR is a
cell surface protein that binds to epidermal growth factor to induce cell proliferation and
is over expressed in many cancers including glioblastoma [15,16]. To support their
extensive proliferation, glioblastomas develop a complex network of blood vessels by
expressing high levels of vascular permeability factor (VPF) and vascular endothelium
growth factor (VEGF) [17]. VEGF is known to increase vascular permeability by
inducing structural abnormalities, opening gaps in the endothelium (biooncology.com)
and negatively regulates tumor cell invasion [18]. Expression of VEGF is associated with
peritumoral edema observed around glioblastomas. Pseudopalisading necrosis –
accidental cell death – is also a hallmark of glioblastoma. Because apoptosis and necrosis
can lead to cell removal, one may think that necrosis is desirable in controlling tumor
growth, however necrosis leads to accelerated tumor growth, as the pseudopalisades
surrounding necrotic regions secrete high levels of proangiogenic factors [19]. A human
T2-weight image demonstrating a Glioblastoma Multiforme tumor is shown in Figure 1.1

Glioblastoma
Tumor

Figure 1.1 Glioblastoma Tumor-An example T2-weighted MRI of a large glioblastoma
tumor is shown in the parietal region of the human brain.
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1.4 Tumor heterogeneity
The response to targeted therapy in cancer patients depends on several factors that
include genotype. Genotype variation exists between patients and within a single tumor
due to the development of subpopulations of cancer cells [20]. Different regions within
the same tumor can have different densities of vasculature and different cellular
composition. Also, tumors may exhibit differences in metabolism and necrosis [21]. At
the time of clinical diagnosis, morphological and physiological features of tumor cells,
such as the expression of cell surface receptors can vary with the type of tumor [22].
Cancer cells that proliferate at a higher rate require more nutrients. To meet this demand,
cancer cells overexpress angiogenic factors such as VEGF and angiogenin [23].
However, tumor cells proliferate more quickly than the vasculature can develop. As a
result the developed vasculature is disorganized and is not able to meet the needs of the
proliferating cells. Cancer cells in the tumor core often lack proper circulation and are
more hypoxic than the cancer cells in the tumor periphery [24]. The unusually developed
vasculature may cause differences in drug delivery to different parts of a tumor. Tumor
heterogeneity may explain variations in the uptake and cytotoxicity of chemotherapy
drugs [25].
1.5 pH regulation in Tumors
The genetic mutations described above and higher rate of glycolysis lead to a
distinguishing feature of malignant tumors, which is higher (alkaline) intracellular pH
(pHi) and lower (acidic) extracellular pH (pHe). The pH is defined as the negative log of
H+ concentration. Under physiological conditions cells maintain their pHi around 7.0
[26,27] and pHe around 7.4. Regulation of this pH homeostasis is important for proper
execution of normal cell function. Deviation from this homeostasis may contribute to the
pathological changes involved in tumor growth. Specifically, in tumors, pHi is alkaline
~7.3 [28,29] and pHe is relatively acidic (around 6.7-7.1). A lower pHe triggers tumor cell
invasion and migration. A higher pHi is permissive of increased cell proliferation and
evasion of apoptosis [30]. In the presence of oxygen, normal cells convert glucose into
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carbon dioxide, which then increases the rate of oxidative phosphorylation to maximize
ATP production by mitochondria while keeping lactate production minimal. Normal cells
only produce higher amounts of lactate when oxygen supply is inadequate. The process
by which this happens is called anaerobic glycolysis; an inefficient way to produce
energy/ATP. In contrast, cancer cells produce large amounts of lactate even in the
presence of sufficient oxygen and therefore cancer metabolism is referred to as aerobic
glycolysis. Due to extensive angiogenesis, tumor cells normally have a good supply of
glucose through the circulating blood and therefore have an increased rate of aerobic
glycolysis. Otto Warburg was the first to realize this deviation from normal metabolism
in tumor cells, which is now known as the “Warburg effect”[31]. The pathways used for
energy production/ ATP production by normal cells and tumor cells under aerobic and
anaerobic conditions is summarized in Figure 1.2.
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Figure 1.2 Schematic representations of the metabolic pathways in normal and
tumor cells. Adapted from Matthew G. et al. [2009, Reference 25]. In the presence of
oxygen, oxidative phosphorylation is the primary path to generate ATP. Normal cells
undergo anaerobic glycolysis (conversion of pyruvate to lactate) only in the absence of
oxygen or when the oxygen source is not sufficient. Warburg observed that tumor cells
undergo aerobic glycolysis (conversion of most of the pyruvate to lactate) regardless of
whether oxygen is present or absent.

Under physiological conditions glycolysis creates acid/protons (H+). This cell-generated
acid has to be extruded to maintain a normal intracellular pH. This transport is performed
by “acid extruders” that move H+ out of the cell (efflux) or move HCO3- into the cell
(influx) resulting in an increased pHi [32]. In addition, “acid loaders” can move H+ into
the cell or HCO3- out of the cell to decrease pH [32]. The most common acid loading
transporters are anion exchangers, which exchange extracellular Cl- for intracellular
HCO3- [33] and Na+ dependent bicarbonate transporters operating in 1:3 stoichiometry
[32]. Acid extruding transporters include Na+ dependent HCO3- exchangers operating in
1:2 stoichiometry, Na+/H+ pumps, and Na+ dependent Cl-/HCO3- exchangers [32-34].
Tumors have elevated production of H+ due to their higher glycolytic rates and therefore
we would expect to see an acidic intracellular pHi [24]. However, in tumors, the excess
protons that are produced are extruded by the combined action of acid extruding ion
transport channels and the CO2/ HCO3-buffer, which is activated in tumors and plays a
major part in maintaining the higher pHi [35]. However, the increased expression or
activity of plasma membrane channels and ion transport channels that facilitate H+ efflux
and HCO3- influx directly or through the CO2/HCO3- buffer pair overcompensate and
produce a higher pHi and lower pHe. The buffer resists the change in pH following the
addition of basic or acidic components. So to maintain a favorable alkaline pH in the face
of excessive proton production in tumors, CO2 exits the cell and dehydrates to form
HCO3- and H+ in the extracellular space (CO2 + H2O ⇋ HCO3- + H+). The HCO3-,
generated in the extracellular space is taken up into the cells where it reacts with
intracellular H+ to form CO2, which will again exit the cell to complete acid removal.
Along with Na+/H+ exchangers, which are over-activated in tumors, the CO2/HCO3-buffer
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plays a major part in maintaining the higher pHi. The role of ‘acid extruders’ and ‘acid
loaders’ is shown in Figure 1.3.
The roll of the CO2/HCO3- buffer is to shuttle H+ within cells. Titration of intracellular
acid with extracellular HCO3- taken up into the cell by acid extruders produces CO2. CO2
is freely membrane permeant and exits the cell to complete acid extrusion [21,36,37].
For effective regulation of pHi by this system, efflux of CO2 has to be in equilibrium with
influx of HCO3- (1:1 stoichiometry). To keep this system in equilibrium the tumor overexpresses the carbonic anhydrase (CA) isozyme and the Aquaporin (AQP) water channel
[38]. So far, about 16 humans CAs have been identified, some of which are extracellular
and some of which are intracellular [39-41].
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Figure 1.3 pH control mechanisms of cancer cells. In tumors, the rate of aerobic
glycolysis is elevated due to increased cell proliferation. The aerobic glycolysis produces
increased lactate and protons. To extrude these, tumor cells increase the expression of
acid extruding ion transport channels such as the Na+/H+ exchangers, sodium driven Cl/HCO3- transporters and Na+/HCO3-cotransporters. To further aid in acid extrusion cancer
cells also increase the expression of CAII, CAIX, CAXII and the AQP1 water channels.
CAII catalyzes the reaction of H+ with HCO3- in the intracellular space to produce H2O
and CO2 (H2O+CO2 H+ + HCO3-). Then AQP1 facilitates the transport of this H2O and
CO2 into the extracellular space where CAIX and CAXII catalyze the hydration of CO 2 to
form H+ and HCO3- (H2O + CO2 HCO3- + H+). The HCO3- generated in the
extracellular space is then taken up into the intracellular space where it again reacts with
intracellular H+ with the aid of CAII and forms H2O and CO2. Now this H2O and CO2
again get extruded in the extracellular space to complete acid removal. In cancer cells,
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this process involving CAs and ion transport channels overcompensates for the increased
production of acid (H+) and produces a slightly alkaline intracellular pH, which is
necessary for their survival and proliferation. Adapted from Boron 2004 [26] and
Yasuhiko Hayashi et al. 2007 [42].

CAs are a group of enzymes that catalyze the interconversion of CO2 and H2O to HCO3and H+ (CO2 + H2O⇋ HCO3 + H+) to keep CO2/HCO3- in equilibrium [41,42]. The
direction of the reaction depends on the form of protons, CO2 or HCO3- that predominates
[43]. So far thirteen human AQP have been discovered [44]. AQP are the water selective
transmembrane transport channels that facilitate CO 2 transport across the membrane
[45,46]. CO2 plays a crucial role in the acidification of the tumor microenvironment
[47,48]. So it is reasonable to speculate that AQP expression could contribute to the
maintenance of pH balance in solid tumors by facilitating CO2 movement and by
providing the substrate for catalytic activity of extracellular CAs. Malignant
glioblastomas express the carbonic anhydrases CAII, CAIX and CAXII, as well as the
AQP1 channel [47]. CAII is expressed in the intracellular space whereas CAIX and
CAXII are expressed in the extracellular space. CAIX is the most active isoform of
carbonic anhydrase for the carbon dioxide hydration reaction [49]. Located in the
extracellular space at the cell membrane, CAIX activity contributes to extracellular
acidification of the tumor micro environment [50,51] and also plays an important role in
maintaining amore alkaline pHi. Previous work has shown that CAIX facilitates CO2
extrusion and CO2 hydration in the extracellular space, which acidifies the extracellular
environment and provides a substrate for intracellular alkalinization [43,51].
Overexpression of these isoforms in many tumors including glioblastoma is associated
poor survival [52,53], cancer progression, and poor response to therapy.

CAXII is

another extracellular tumor CA isozyme [54,55]. CAXII activity may compliment CAIX
activity to facilitate CO2 extrusion in the extracellular space and regulate acidic
extracellular and alkaline intracellular pH [43,56]. CAII catalyzes the diffusion of
intracellular H+ with HCO3-, which is taken up in the intracellular space (cytoplasm) by
the sodium-driven Cl-/HCO3- exchanger or sodium bicarbonate cotransporters (Na +-
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HCO3-cotransporters), producing H2O and CO2 [43,44]. Several pH regulation
mechanisms in tumor cells are summarized in Figure 1.4. The red box highlights the role
of intracellular CA, extracellular CA and the AQP1 water channel in tumor pH
regulation.

Figure 1.4 The roll of CA and AQP1 in tumor pH regulation. In tumor cells aerobic
glycolysis is elevated causing increased production of lactate and H+. This
overproduction would normally lead to acidic an intracellular pH. However, cancers cells
adaptively increase the expression of membrane ion transport channels to extrude the
intracellular H+ into the extracellular space. Also, to balance the acid load, the activity of
CAII, CAIX, CAXII, and AQP1 increase in cancer cells (red box).
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1.6 Tumor Detection
Exogenous Contrast: Tumors develop extensive microvasculature which is leaky. Many
tumor diagnostic methods exploit these micro vascular changes to identify and monitor
tumor growth. These methods often involve intravenous injection of an exogenous
contrast agent. Depending on the molecular size and its charge, a contrast agent either
remains in the vasculature or enters the cells.
Dynamic contrast enhanced MRI (DCE-MRI) involves serial acquisition of MR images
before and after intravenous injection of a contrast agent, and is one of the most
acceptable exogenous contrast agent methods used clinically. DCE-MRI typically uses
the gadolinium based contrast agent, Gd –DTPA [23,57]. Through the bio-distribution of
the agent, properties of the underlying tissues can be determined. In normal brain tissues
the blood brain barrier is intact and the agent remains in the vasculature. However in
tumors, where the vasculature is leaky the contrast agent can accumulate [58]. The
gadolinium based contrast agents reduce the longitudinal relaxation time, T 1, of local
water molecules resulting in an increase in the MRI signal on T1-weighted images. This
increase in signal is related to the concentration of agent. By fitting dynamic DCE-MRI
data to an appropriate pharmacokinetic model, physiological parameters related to tumor
vasculature such as vessel permeability and tissue perfusion can be determined [59]. For
example, a quantitative DCE-MRI study in patients with breast cancer receiving
longitudinal neoadjuvant chemotherapy showed decreased perfusion within these tumors
after therapy [60].
Other contrast agents modify the magnetic susceptibility of the tissue, which reduces the
local measured transverse relaxation time (T 2*). These agents stay within the vasculature
- therefore they are mostly used to characterize blood vessel size and volume. Receptor
targeted contrast agents are also widely used for molecular imaging of tumors as cell
surface receptors are upregulated on tumor cells and endothelial cells within the tumor
vasculature [61]. Also, there is a growing interest in developing chemical exchange
saturation transfer (CEST) contrast agents for MRI. These agents have exchangeable
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protons, which can transfer magnetization to bulk water after irradiation at their specific
absorption frequency. This decreases the observed water signal intensity creating contrast
between tissues of interest. Recently a PARACEST agent was used to detect glioma in a
mouse model [62,63].
Similar to DCE-MRI, positron emission tomography (PET) provides functional and
metabolic assessment of normal and diseased tissue. PET most often uses fluorine 18fluorodeoxyglucose (FDG) for tumor detection. This tracer of glucose consumption is
effective in tumors due to increased glucose metabolism and has been proposed as an
early metabolic marker of cancer treatment. However FDG uptake also increases in
conditions such as infection and hyperplasia, which can result in false positives.
All these methods for tumor detection require the injection of an exogenous contrast
agent or tracer and a lengthy trial process to determine if the agent is safe to use in
humans. Also, there are potential issues regarding the use of approved agents, such as the
requirement for high concentrations of a contrast agent to achieve adequate detection
sensitivity, the bio-distribution of contrast agents in tissues other than the intended one,
and the inability of contrast agents to enter into poorly perfused tumor regions, or
necrotic tissue. These shortcomings have led researchers to develop endogenous contrast
mechanism for different modalities.
Endogenous Contrast: Endogenous contrast mechanisms are completely non-invasive
and avoid the undesirable issues associated with the use of exogenous contrast agents.
Currently, anatomical imaging is widely used by radiologists in clinics to detect tumors
and monitor tumor response to treatment by observing the size and shrinkage of tumor
tissue using CT [64]. However, these measurements vary between different observers due
to difficulties in determining tumor boundaries. Also, tumor size is not a reliable marker
of therapy response as it is influenced by the rate of regrowth. The evaluation of
antiangiogenic treatment in a murine model of melanoma by Power Doppler Ultrasound
using perfusion and vascularity matrices has shown a decreased rate of blood flow in
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angiogenic blood vessels, 1-3 weeks after the use of antiangiogenic treatment [65]. But
this method can’t be used when the tumor is blocked by dense structures such as bone,
which inhibits the penetration of the ultrasound beam.
Magnetic Resonance Imaging (MRI) of endogenous molecules has been shown to be a
highly sensitive method to detect cancer, with a wide variety of contrast mechanisms
available to exploit. MRI offers detailed information about anatomical changes, changes
in diffusion, and tissue volume due to apoptosis [66]. Magnetic Resonance spectroscopy
(MRS) can detect metabolic characteristics of cancer arising from different metabolites
[67] including creatine, total choline, lactate, and N-acetyl aspartate. Although highly
informative, the resolution of MRS is severely limited by the concentration of
endogenous molecules present in the tissue. MR thermometry can be used to monitor
hyperthermia and ablative therapy [68]. Diffusion weighted imaging (DWI) has been
used to measure the apparent diffusion of water in different tissue compartments. An
increase in the apparent diffusion coefficient after chemotherapy has been shown to
indicate a positive response to the treatment [69]. Magnetization transfer (MT) is another
contrast mechanism in MRI, which can modulate the observable net magnetization of
bulk water protons through the interaction of these water protons with macromolecules in
the tissues. The exchange of magnetization can occur by dipolar coupling or by chemical
exchange [70]. MT has been shown to be sensitive to the characteristics and composition
of brain tumors. The MT effect is measured by the magnetization transfer ratio (MTR)
which is calculated by subtracting positive frequencies from the negative frequencies of
the MT spectrum [71]. A study investigating the histological constitution of brain tumors
showed significantly lower MTR for tumors than for normal tissues [72]. The amide
proton transfer (APT) technique developed by Zhou et. al. [73], detects a decrease in the
MRI water signal by selectively exciting off resonance amide protons on intracellular
proteins and peptides. Zhou demonstrated that the efficacy of magnetization transfer was
affected by pH, suggesting that chemical exchange saturation transfer (CEST) [73] was
pH dependent.
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1.7 Treatments and relevance to pH
Because the higher intracellular pH in cancer cells is thought to resist the initiation of
apoptosis, selective intracellular acidification has been proposed as a potential cancer
treatment [74,75]. Some studies have also shown that the thermosensitivity of tumor cells
increases at lower intracellular pH [76,77]. In addition, researchers have postulated that
internucleosomal DNA fragmentation, the process of inducing cell death, requires
intracellular acidification [78,79]. At the same time higher intracellular pH has been
shown to reduce the effectiveness of the drug cisplatin, which is commonly used in
chemotherapy [80]. Also, the uptake of a therapeutic agent into the cell is affected by the
pHe/pHi gradient. Most chemotherapy drugs are either weak acids or weak or bases.
Passive diffusion of these drugs into the cells occurs mostly in their uncharged form.
These drugs accumulate by diffusion into the oppositely charged compartment. Due to
the effect of the pHe/ pHi gradient in cancer cells, basic drugs accumulate in the acidic
extracellular space putting them at a therapeutic disadvantage [81]. The effect of the
pHi/pHe gradient on drug distribution is summarized in Figure 1.5.

Figure 1.5 Effect of pHe/pHi on distribution of drugs. The font size indicates the
relative concentration in that compartment. The cell membrane functions as a semi
permeable structure that is permeable to uncharged drugs and tends to remain
impermeable to charged drugs. As the extracellular space of tumors is acidic, the weak
acid drugs remain uncharged and therefore are more easily taken into the intracellular
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space. Whereas, in the acidic extracellular space weakly basic drugs becomes charged
and therefore do not pass through the cell membrane [81].

The complex interaction between intracellular pH and the therapy options for the tumor
motivates the use of imaging techniques like CEST which have been used in the past to
generate maps of pH distribution. In addition, the selective intracellular acidification of
cells is emerging as a potential enabler of cancer therapy to increase the therapeutic
potential of existing drugs [82]. It is the primary goal of the work presented in this thesis
to determine the pHi lowering potential of the antiepileptic drug Topiramate in a cancer
model using CEST MRI.
1.8 Modification of Tumor pH using Carbonic Anhydrase Inhibitors
1.8.1 Topiramate
Topiramate is a well-known carbonic anhydrase inhibitor (CAI) and is an anticonvulsant
(antiepileptic) drug. It is approved in humans as a monotherapy or adjunctive therapy in
the treatment of epileptic seizures as well as in the treatment of migraines [83].
Monotherapy doses of topiramate as high as 400 mg/day are used in humans whereas in
adjunctive therapy in placebo controlled clinical trials, doses of 1000 mg/day have been
used [84,85]. Epilepsy is common in patients with brain tumors and can complicate the
management of these patients due to the possible interaction between antiepileptic drugs
and anticancer drugs. It has been shown that Topiramate is well tolerated in patients with
brain tumors associated with seizures [86]. Considering this fact, it is interesting to
explore the potential metabolic effect of topiramate on brain tumors as the drug may
impair the activity of tumor associated CAs which are one of the mechanisms use by
tumors to maintain an elevated pHi [87].
1.8.2 Mechanism of pH Modification
Many reports have demonstrated the over expression of intracellular CAII and
extracellular CA IX and CAXII in tumors [88,89] and described their role in maintaining
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higher pHi. Topiramate has been shown to inhibit all of these CAs to some extent,
however topiramate more effectively inhibits CAXII and CAII than CAIX [41].

A brief introduction to the regulation of elevated pHi by the above mentioned CAs is
given in this paragraph. In the extracellular space CAIX and CAXII catalyze the
hydration of CO2with H2O to produce HCO3- and H+. The extracellular HCO3- is rapidly
transported into the cell by Na+ dependent Cl-/HCO3- or Na+ dependent bicarbonate cotransporters (1:2 stoichiometry). The intracellular HCO3- then reacts with intracellular H+,
lowering proton concentration (thus increasing pHi), and producing CO2 and H2O by the
catalytic action of intracellular CAII. This intracellular CO2 again gets shuttled out of the
cells rapidly and the cycle continues, keeping pHi elevated [37]. The Zn2+ ion present in
all CAs is responsible for their catalytic action. CAIs including Topiramate bind to the
Zn2+ ion of the CAs to form a tetrahedral adduct which limits their catalytic activity [41].
A study by Leniger et.al., observed a decrease in pHi of hippocampal neurons caused by
topiramate. Leniger concluded that topiramate inhibits the activity of intracellular CA and
speculated that topiramate may also impair the activity of Na+ dependent Cl-/HCO3exchange, the acid extruder, and increase the activity of Na+ independent Cl-/HCO3exchange, the acid loader (Figure 1.3) [90].
1.9 Tumor pH measurements
1.9.1 Techniques of pH measurements
Change in pH homeostasis underlies many pathological conditions including cancer and
in conditions of ischemia. Hence, many researchers are developing new techniques for
pH measurement. In the past, pH electrodes were the first choice for pH measurements.
However they are prone to inaccurate pHi measurements caused by physical damage to
the cells [91].
PET has also been used to measure extracellular pH of tumors in patients using the pH
probe
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C-labeled dimethadione (DMO) [92]. The probe is injected and the pH is
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calculated from the distribution of charged and uncharged species of the probe. To
measure pH using dimethadione also requires knowledge of DMO concentration in tissue
water, the concentration of DMO in the extracellular space, and the volume of the intraand extracellular spaces. The measurements of these parameters are complicated and
introduce errors into the pH measurements [93,94].
Optical methods can also be used to measure pH in tumors and surrounding tissues using
the fluorescent properties of optical probes [95]. There are two main optical approaches
used to measure pH. The first is fluorescence ratiometric imaging microscopy, a method
in which the emission spectra of the probe undergoes a pH dependent wavelength shift
and pH is determined by measuring the fluorescence intensities of these spectra. However
the association of the emission properties of these probes with intracellular protein and
cytosolic content can introduce bias in the measurement. The second is fluorescence
lifetime imaging, which measures the fluorescence decay of the pH probe, and can be
used to measure pH using the pH dependent shift in fluorescence lifetime of the pH probe
[95]. Several magnetic resonance (MR) methods have also been developed to measure
pH of tissues.
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P-Magnetic resonance spectroscopy (MRS)can be used to measure pHi

[96]. pHi is measured from the pH dependent chemical shift of inorganic phosphate (P i)
with reference to that of phosphocreatine (PCr) [67]. However in tumors where necrotic
volumes may develop, the concentration of extracellular Pi may elevate abnormally and
may also contribute to the measurement making the measured pH weighted to both
environments [28,97]. Extrinsic and intrinsic pH probes have also been developed for
1

H- MRS to measure extracellular and intracellular pH respectively. Van Sluis et. al. [98-

100] have measured extracellular pH using the extrinsic pH probe 2- imidazole- 1- yl- 3ethoxycarbonyl propionic acid (IEPA) in a mouse model of breast cancer. The CH2 group
resonance of IEPA is pH sensitive and therefore can be used to measure pH. The
intracellular pH measurement by 1H –MRS uses the pH dependent chemical shift of the
two protons on the C-2 and C-4 (Im_C2 and Im_C4) resonances of the imidazole ring, of
intracellular histidine but also requires administration of exogenous histidine as the
endogenous concentration of this compound is too low to detect [98-100].
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Hyperpolarized

13

C bicarbonate is another method to measure pH and involves

administration of hyperpolarized H13CO3- [29,101]. This method was recently used to
measure pH of lymphoma xenografts in a mouse model. The measurement showed the
pHe of lymphoma is significantly lower than that of the surrounding normal tissue. The
tumor pH was measured from the voxel wise ratio of [H13CO3-] to [CO2]. A similar
approach has been used to map intracellular pH in the ischemic rat heart by injecting
hyperpolarized [1-13C] pyruvate which is decarboxylated in mitochondria to form CO 2
and H13CO3- [29,101,102]. However the measurement of pH using this method requires
fast imaging as the signal from hyperpolarized
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C decreases rapidly. The method also

suffers from limited spatial resolution.
MR relaxometry measures tissue pH by perturbing the relaxivity of bulk water protons
via pH-sensitive relaxation agents such as gadolinium complexes. The pH sensitive agent
GdDOTA-4AmP5 developed by Sherry and colleagues and Aime and colleagues has been
shown to have pH sensitive relaxivity [103,104]. Measurement of pH by this method
requires precise measurement of agent concentration within each voxel as the relaxation
also depends on the concentration. To solve this problem Raghunand et. al. have used
serial injection of two different gadolinium agents, GdDOTA-4Amp5 whose relaxivity is
pH dependent and GdDOTP5 whose relaxivity is pH independent. They have mapped
pHe in mouse kidneys [105] and in rat glioma [106]. With this method the pH insensitive
agent is injected first. After washout of the first agent the pH sensitive agent is injected.
The concentration of pH sensitive agent is determined by the distribution of pH
insensitive agent and then used to measure pHe. However this method is invasive and
requires injection of exogenous contrast agents. In MRI, Chemical Exchange Saturation
Transfer (CEST) is an emerging technique for measuring pHi and has received
considerable attention. The underlying principles of the CEST technique used to measure
pHi will be described in the following sections.
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1.9.2 Chemical Exchange Saturation Transfer (CEST)
1.9.2.1 Origin of Nuclear Magnetic Resonance (NMR) signal
In MRI the measured signal is typically derived from the net magnetization of H+ in bulk
water. When a nucleus with spin angular momentum is placed in a magnetic field, the
magnetic moments tend to align either in the direction of the magnetic field (low energy
state) or in the opposite direction of the magnetic field (high energy state). At
equilibrium, the number of spins in the low energy state slightly exceeds those in the high
energy state and this produces a net magnetization of the system which can be thought of
as a spin vector aligned with the magnetic field. Interaction between this net
magnetization with an applied radio frequency pulse produces the observable signal in
MRI.
1.9.2.2 Two pool proton exchange system
The concept of CEST involves the chemical exchange of protons that are present in a
different chemical environment and resonate at different frequencies (ω) than bulk water
protons. For the explanation of CEST, consider a two-pool system of exchanging protons.
The first pool is a small pool of bound water protons (solute protons called pool A) found
on intracellular proteins and peptides in tissues. The protons are rigidly bound to the
surface of intracellular proteins and take a long time to change in position compared to
the bulk water protons. In many cases these protons are amide or amine protons with
concentration in the mM or µM range. The second pool is a large pool of free water
protons (bulk water protons called pool B) with concentration about 55M as shown in
Figure 1.6 below.
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Figure 1.6 Schematic presentation of a two-pool system involved in proton exchange.
The smaller pool A (solute pool) is composed of amine or amide protons associated with
proteins in the tissue and the larger pool B is composed of the bulk water proton pool.
The protons from the solute pool are always in chemical exchange with the bulk water
protons. The process of chemical exchange depends on the concentration of the two pools
and their proton exchange rates, referred to here as Ksw and Kws.

To observe a CEST effect by MRI, the exchange rate of the proton should be in a slow to
intermediate exchange regime. This means the proton exchange rates must not exceed the
frequency difference (∆ω) of the two pools i.e. Kws, Ksw≤ ∆ω. Also, the longitudinal
relaxation rate (R1) of the solute proton pool must be slower than its exchange rate with
bulk water protons. Excellent reviews describing the CEST MRI contrast mechanism
have recently been published [107,108].
1.9.2.3 Saturation and Chemical Exchange
If the exchanging system of protons satisfies the above mentioned conditions,
presaturation of the solute protons can modify the population of the spin energy levels of
this pool. At equilibrium (before interrogation with an RF pulse) fewer proton spins are
aligned in the high energy state (in the opposite direction of the magnetic field, Figure
1.7A). When a radio frequency pulse (RF) of suitable energy is applied at the offset
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frequency of the solute protons, the number of solute proton spins in the high energy state
increases. As the number of proton spins in low energy states decreases, the bulk
magnetization of this pool will be reduced. When the number of proton spins in both
energy states becomes equal the spins are said to be saturated and the net magnetization
of the pool will be zero. The proton spins in the bulk water pool initially maintain their
distribution according to the Boltzman Equation (Figure 1.7B). However, once the solute
pool becomes saturated, the exchange of spins to the bulk water pool perturbs this
equilibrium condition (Figure 1.7C). The exchange process takes place in two directions.
The net effect is a reduction in the population difference between the low and high
energy states in the bulk water pool. This “chemical exchange” effect results in a
decrease in the net macroscopic magnetization of the bulk water pool along the z-axis. If
the protons in the solute pool have a fast forward exchange rate and the saturation time is
sufficiently long (in the range of seconds), the effect of the saturation of the solute pool
will be to decrease the magnitude of the bulk water magnetization. This means that when
a 900 pulse is applied to measure the magnetization, the signal intensity of the bulk water
pool will be lower than with no saturation applied [107,109,110] (Figure 1.7D).

Figure 1.7 Process of saturation and chemical exchange. A) At equilibrium (before
application of an RF pulse) the population of spins in the low energy state is higher than
that of the population of spins in high energy state. B) When an RF saturation pulse is
applied at the resonance frequency of pool B, the population of spins in the high energy
state in this pool increases, which results in a decrease in net magnetization of this pool.
Without exchange, the water maintains its equilibrium distribution of spins. If the RF
saturation pulse is of sufficient duration then the process of saturation equalizes the
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number of proton spins in the two energy levels. C) When pool B is in exchange with
pool A, the magnetization from pool B is transferred to pool A. D) As a result of the
transfer of energy from pool A to pool B, the signal from the bulk water pool B
decreases. Adapted from reference [101]

The theory of chemical exchange has also been extended to three or four pools of
exchanging protons including a pool of free (bulk water) protons and additional pools of
bound protons [111,112].
1.9.2.4 Chemical Exchange and pH
The cellular environment in humans contains several different proton exchanging systems
including the amide and amine protons of intracellular proteins and peptides, the
hydroxyl (-OH) protons present in sugar, cellulose and glycogen, and free water protons.
The rate of chemical exchange of these protons is pH dependent; exchange increases with
higher pH. Recently, Zhou and coworkers used CEST contrast arising from intracellular
proteins and peptides to acquire pH-weighted images of rat brain with ischemic regions
and tumors. The CEST contrast was named amide proton transfer (APT) [73]. Our
laboratory has also recently developed a ratiometric CEST contrast technique called
Amine and Amide Concentration Independent (AACID) detection. AACID is a ratio of
CEST effects arising from amide protons resonating at 3.5 ppm (parts per million) and
amine protons resonating at 2.75 ppm downfield from the bulk water protons. This
technique was successfully applied to measure pH changes in glioblastoma tumors after
the selective acidification of the tumor environment with a drug called lonidamine [113].
However lonidamine is not currently approved for use in humans. Therefore the goal of
this thesis was to apply the AACID technique to measure pH changes induced by a single
dose of the drug Topiramate, which is a well-established and approved anticonvulsant.
1.9.2.5 Chemical Exchange Saturation Transfer (CEST) measurements
CEST contrast measurements are made by acquiring a spectrum called a Z-spectrum; also
commonly called a CEST-spectrum. A radiofrequency saturation pulse is applied at a
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predefined set of frequencies offset from the water resonance frequency. Following each
application of the saturation pulse, the bulk water signal is measured. The CESTspectrum is created by plotting the acquired bulk water signal intensity (magnetization) as
a function of the applied saturation frequency. The resonance frequency of the bulk water
is generally used as the center frequency and is assigned the chemical shift of 0 ppm.
When the presaturation frequency is far away from the water resonance frequency, there
is no direct saturation of the bulk water pool. But, if the frequency of the saturation pulse
is at or close to the water resonance frequency, then the intensity of water signal
decreases due to its direct saturation. This produces a negative peak in the CESTspectrum. Similarly, if the saturation frequency is at the resonance frequency of an
exchangeable solute proton pool (amide or amine), the process of saturation and chemical
exchange will decrease the intensity of the bulk water signal, which will also produce a
negative peak in the spectrum. In a system involving three pools of exchanging protons
the CEST spectrum will have three negative peaks representing each pool. The observed
CEST effect may be pH dependent. A CEST- spectrum of an exchanging system (three
pool model) is depicted in Figure 1.8
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Figure 1.8 CEST spectra obtained from a three-pool proton exchanging system at
different pH. When the RF saturation pulse frequency is applied far from the water
resonance frequency there is no effect on the water magnetization. However when the
frequency of the saturation pulse is applied at the amide resonance (3.5 ppm) or amine
resonance (2.75 ppm), the process of saturation and chemical exchange decreases the
signal intensity of the measured bulk water resulting in a dip in the CEST spectrum. M 0
is the bulk water magnetization without saturation and M Z is the measured bulk water
magnetization following saturation. Adapted from Ref. [114]

1.9.2.6 Water Saturation Shift Referencing (WASSR) for CEST experiments
The phenomenon of CEST exploits the transfer of magnetization from solute protons to
bulk water protons. At 9.4 T, the amide protons (3.5 ppm) and amine protons (2.75 ppm)
resonate relatively close to the water frequency (assigned a resonance frequency of 0
ppm). The measured change in bulk water magnetization commonly referred to as the
CEST effect from amine and amide protons, is influenced by many factors including the
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bulk water relaxation rate R1, the exchange rate, the presence of magnetization transfer
(MT) effects arising from immobile semisolid macromolecules (such as lipid), and B 0
inhomogeneity. Macromolecular protons have a wide absorption range 1-50 kHz and are
also saturated by the off resonance RF preparation pulse. The transfer of magnetization
from these protons to bulk water competes with the CEST effects from the solute proton
pools of interest. Also, in vivo, CEST effects are extremely sensitive to direct water
saturation. Due to the steep slope of the direct water saturation curve any inhomogeneity
in the main magnetic field B0 can shift the frequency of the water resonance in the CEST
spectrum and can reduce the magnitude of the observed CEST effect.
To solve this problem Kim et. al. proposed a technique called Water Saturation Shift
Referencing (WASSR) [115]. In WASSR a set of images is acquired ranging the RF
preparation pulse frequency in small steps around the bulk water frequency using a low
saturation power to reduce the MT effects and CEST effects from other exchanging
systems. Polynomial fitting is then used to find the center of the Z- spectrum in each
voxel.
For this study, WASSR spectra were acquired before the acquisition of each CEST
spectrum by applying a saturation pulse of duration 100 ms and amplitude 0.2 µT. Each
WASSR spectrum was interpolated to achieve a 1 Hz resolution and was then fitted to a
polynomial to find the center peak in each voxel.
1.9.2.7 CEST - pH calibration (AACID- pH calibration)
Our group has recently developed a radiometric CEST measurement technique called
Amine and Amide Concentration Independent Detection (AACID). To relate the
measured AACID value to pHi, a calibration was required. In our study, CEST spectra
were acquired in normal healthy mice (N= 3) and mice with brain tumors (N=8) using the
method described above. In each mouse the average AACID values were calculated
directly from the B0 corrected CEST spectra using Equation [1] in the normal mouse
brain and contralateral region for mice with tumors, as well as within the tumor region
[114].
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[1]

Contrast maps were also generated by calculating the contrast to noise ratio (CNR) using
Equation [2] where CESTTPM represents the average CEST parameter value calculated
after the TPM administration and CESTBaseline represents the average CEST parameter
value prior to TPM treatment.

[2]
To relate AACID values to pH, we used data from three healthy mice and eight tumor
mice. In healthy mice, the whole brain AACID values were averaged. The calculated
AACID values in non-tumor and tumor regions were plotted against expected pH values
from the literature and the points were fitted to a linear model [114,116]. For this
calibration, contralateral tissue in mice with tumors was considered to be normal. The
measured AACID values in the contralateral ROIs and AACID values in normal mouse
brain were assigned a pHi= 7.0 [26,27] whereas, AACID values in tumor ROIs were
assigned to pHi= 7.3 [28,29]. The resulting linear relation described in Equation [3] was
used to generate in vivo pH.
[3]
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1.10 Thesis Objective
In summary, one of the features that all aggressive cancers share is higher pH i and lower
pHe. Higher pHi in tumors is associated with tumor growth and evasion of apoptosis
[30,117] whereas lower pHe is associated with invasive growth and cell migration
[30,118]. Higher pHi also suppresses the cytotoxic effects of alkaline anticancer drugs
[119]. We hypothesize that it is possible to exploit the differences between tumor pH,
healthy tissue pH, and pH regulation, for cancer detection and treatment. Specifically, in
this thesis we will explore pharmacological manipulation of intracellular pH and direct
monitoring of acute pH changes by MRI. For this work we have selected the antiepileptic
drug Topiramate, which is approved for use in humans and has been shown to be well
tolerated and effective in controlling seizures in patients with glioblastoma [86]. The
objective of this thesis was to determine whether the antiepileptic drug Topiramate can
modulate tumor pH and if these changes are detectable by AACID-CEST.
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Chapter 2
Topiramate Induced Acute Intracellular Acidification in Glioblastoma
Multiforme Brain Tumors
Kamini Marathe, Nevin McVicar, Alex Li, Miranda Bellyou, Susan Meakin,
And Robert Bartha
Abstract: Reversal of the intracellular/extracellular pH gradient is a hallmark of
malignant tumors and is an important consideration in evaluating tumor growth potential
and the effectiveness of anticancer therapies. Brain tumors including Glioblastoma
Multiforme (GBM) have increased expression of the carbonic anhydrase (CA) isozyme
CAII, CAIX and CAXII that contribute to the regulation of intracellular pH (pH i). The
anti-epileptic drug topiramate (TPM) inhibits these tumor associated CAs and may
acidify the tumor intracellular compartment. In-vivo detection of acute tumor
acidification could aid in cancer diagnosis and treatment optimization. Chemical
exchange saturation transfer (CEST) magnetic resonance imaging (MRI) has been used to
measure tissue pH. Using a recently developed CEST-MRI method called amide/amine
concentration independent detection (AACID) we have previously shown intracellular
acidification caused by a single dose of lonidamine. However lonidamine is not currently
approved for use in humans. Therefore the aim of the current study was to evaluate the
intracellular acidification induced by single dose of the approved drug Topiramate. Brain
tumors were induced in NU/NU mice by injecting 1×105 U87 human glioblastoma
Multiforme cells into the right frontal lobe. Using a 9.4T MRI scanner AACID CEST
spectra were acquired, before and after administration of TPM (dose: 120mg/kg
intraperitoneal) 15 ± 2 days after tumor cell implantation. A significant average 0.12
decrease in pHi was observed in implanted tumors one hour after TPM administration. In
contrast, contralateral tissue showed no change in pHi. These results suggest that
topiramate can rapidly induce a tumor specific physiological change detectable by
AACID CEST. This pH challenge paradigm could be exploited to aid in tumor detection
and treatment planning.
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Keywords: Carbonic anhydrase inhibitor, Topiramate, magnetic resonance imaging,
chemical exchange saturation transfer, AACID, tumor, intracellular pH.
Abbreviations used: CEST-Chemical Exchange Saturation Transfer; CA-Carbonic
Anhydrase; CAI- Carbonic Anhydrase Inhibitor; GBM- Glioblastoma Multiforme;
AACID- Amine and Amide Concentration-Independent Detection; pHi- Intracellular pH;
TPM- Topiramate, TR-Repetition Time, TE- Echo time, ETL- Echo Train Length, FOVfield of View
2.1 Introduction
Glioblastoma Multiforme (GBM) is the most aggressive and common form of primary
brain cancer accounting for < 2% of all cancers but remains one of the most lethal human
malignancies [1-3]. In patients receiving standard treatment, involving surgical resection
followed by aggressive adjuvant radiation therapy and chemotherapy with temozolomide,
the median survival is approximately 12-18 months after diagnosis [4,5]. Despite
advances in anticancer therapies, management of patients with GBM represents a severe
challenge as 90% of tumors recur due to the infiltrative nature of GBM cells [6]. The
therapy options for recurrent glioma are limited, reducing the survival rate to 3-6 months
in these patients [7]. Identifying progression is difficult by magnetic resonance imaging
[8] as morphological changes induced by anticancer therapies, such as radiation necrosis,
mimic that of recurrent brain tumor [9].

Identifying a positive tumor response to

treatment can also take several weeks when using conventional methods of measuring
tumor size [6]. Therefore, there is a need to develop sensitive imaging techniques that can
identify malignant cells and accurately characterize tumor response to treatment within a
short time interval.
One of the distinguishing features of cancer cells is the reversed intracellular/
extracellular pH gradient. Tumors cells maintain a slightly alkaline intracellular pH (pH i)
compared to normal cells, whereas the extracellular pH is more acidic. Higher pH i is
permissive of increased proliferation, cell migration, and evasion of apoptosis and is also
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associated with resistance to chemotherapy drugs in cancer management [10,11]. Cancer
cells regulate this reversed cellular pH gradient favorable to their survival through
changes in the expression of ion transport channels and the CO2/HCO3-buffering system
[10,12,13]. The CO2/HCO3- buffering system helps to maintain acid / base balance to
regulate pHi and minimize the effect of pHi variation in response to intracellular H+
production or H+ consumption. For the CO2/HCO3- buffer to effectively regulate pHi, the
influx of HCO3- must match the efflux of CO2 [13]. To maintain buffer system
equilibrium and pH homeostasis, cancer cells over express the hypoxia inducible
carbonic anhydrase (CA) isozyme-CAII, CAIX and CAXII, as well as Aquaporin water
channels (AQP1) [14-17].The carbonic anhydrases are zinc enzymes and play a crucial
role in pHi regulation by catalyzing the reversible hydration of CO 2 (CO2 + H2O ⇋
HCO3- + H+) and by enhancing the efflux of CO2 into the extracellular space [14,15,18],
which is a disguised form of acid extrusion. The direction of the reaction depends on the
concentration of protons, CO2, and bicarbonate that predominates [15]. AQP1 facilitates
transport of intracellularly generated CO2into the extracellular space and thus plays an
important role in pH regulation [19]. Inhibition of the carbonic anhydrases CAs,
particularly by carbonic anhydrase inhibitors (CAI) has been shown to modulate pHi invitro in tumors [20,21]. Perturbing the pHi balance by pharmacologically manipulating
these regulating mechanisms could provide a tool to rapidly assess tumor physiology and
potentially predict response to specific treatments [22].
We have recently developed and applied a novel chemical exchange saturation transfer
(CEST) technique called amine and amide concentration independent detection (AACID)
to monitor changes in tissue pHi. Within the physiologically relevant range, AACID
values have a linear dependence on pHi [23]. We have demonstrated tumor selective
acidification using the AACID technique in a mouse model of GBM approximately 50
minutes after administration of a single dose of the anticancer drug-lonidamine (LND)
[24]. However LND is not currently approved in humans. In contrast, the drug
Topiramate (TPM) is widely used in humans for the treatment of epileptic seizure [25].
This drug is a sulfonamide derivative that binds to the zinc ion site necessary for catalytic
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activity of CAs and acts on most CA isoforms disturbing their ability to regulate pH i [14].
More specifically, it is been proposed that inhibition of CAs disturbs the CO2/HCO3equilibrium causing intracellular acidification [13]. Interestingly, treatment of Lewis lung
carcinoma with TPM has shown a significant reduction of lung metastases, potentially
due to the effect of TPM on CAs and AQP1 [26].The purpose of the current study was to
measure the change in pHi induced in GBM tumors by a single dose of TPM using
AACID CEST MRI. We hypothesized that a single dose of TPM would produce tumor
specific acidification detectable by CEST MRI contrast. Manipulating pH regulation in
tumor cells using pharmacologic stressors, such as topiramate, may provide a sensitive
tool for the detection of tumor boundaries as well as an indicator of tumor response to
treatment, as the physiological response to the pharmacologic stressor varies with cell
type.
2.2 Methods
2.2.1 Subjects: Eleven NU/NU mice were included in the current study. Eight of these
mice were implanted with U87MG brain tumors and used to evaluate the acute effect of
TPM on tumor pHi. The remaining three NU/NU mice were used as controls to study the
effect of TPM on the pHi of normal brain tissue.
2.2.2 Chemicals: TPM (C12H21NO8S) was purchased from Sigma-Aldrich (Aldrich,
Canada) in powder form. The drug was prepared by dissolving 50 mg of TPM in 10 ml
of phosphate buffered saline (PBS, pH=7.2). The solution was vortexed for 2 minutes to
dissolve the drug completely. Following baseline imaging as described below, TPM was
administered intraperitoneal (i.p.) at a dose of 120 mg/kg over the course of 5 minutes
using a Harvard apparatus (PHD 2000) syringe pump.
2.2.3 Mouse Tumor preparation: The human glioblastoma multiforme cell line U87MG
(malignant glioma cells) was purchased from ATCC (Rockville, MD). Tumors were
induced in eight NU/NU mice (10-12 weeks old, weighing 20-25 gm) as described
previously [23]. Briefly, GBM cells were grown in Dulbecco’s modified Eagles medium
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supplemented with 10% fetal bovine serum (Wisent Inc.) at 370C in a humidified
incubator with 5% CO2 and passaged twice a week. Before making the final solution of
1×105 U87MG cells in 2ml PBS for injection, U87MG cells were washed and dissociated
with phosphate buffered saline (PBS) plus 0.5 mM EDTA and then washed twice with
PBS alone. Before injection of the cells, anesthesia was induced in each mouse by
inhalation of 4% isoflurane in oxygen through a nosecone with the head secured in a
stereotactic frame (Stoelting instruments, Wood Dale, IL, USA). Anesthetized animals
were maintained using 1.5-2.5% isoflurane. The scalp was swabbed with a 3-step surgical
prep and bregma was exposed by making an incision in the scalp. A 1 mm diameter hole
was drilled in the skull at coordinates 1 mm anterior to bregma and 2 mm lateral from
midline, to allow injection of cancer cells through a 27-guage Hamilton syringe. The
U87MG cells, (2 μl), were manually injected over a 5 minute period into the right frontal
lobe, 3 mm into the tissue (from bregma) with a Hamilton syringe (Reno, NV, USA)
attached to a 27-gauge needle. The needle was left in place for an additional 3 minutes
before withdrawing. The burr hole was covered with bone wax and the scalp was sutured
closed.
2.2.4 Mouse preparation for in-vivo imaging: Mice were prepared for imaging 15 ± 2
days post tumor cell injection. The mice were anesthetized using 4% isoflurane in oxygen
and maintained with 1.5-2.5% isoflurane in oxygen. Each mouse was positioned and
secured on a custom-built MRI-compatible stage. The mouse’s head was secured using a
bite bar and surgical tape to minimize motion due to respiration. Mouse temperature and
respiration was monitored throughout imaging. A rectal temperature probe was used to
monitor temperature and a pressure transducer attached to a respiratory sensor pad was
placed on the thoracic region to monitor respiration. Throughout imaging, mouse body
temperature was maintained at 36.9-37.5 0C by blowing warm air over the animal using a
model 1025 small-animal monitoring and gating system (SA Instruments Inc., Stony
Brook, NY, USA). All animal procedures in this study were performed according to a
protocol approved by the University of Western Ontario Animal Use Subcommittee.
Animals were sacrificed immediately after MR imaging.
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2.2.5 In-vivo Magnetic Resonance Imaging: At day 15 ± 2 after cancer cell injection,
the mice were imaged on a 9.4T small animal MRI scanner equipped with a 30 mm
millipede volume coil (Agilent, Santa Clara, CA, USA). Standard anatomical T 2weighted images were used for tumor visualization. The T2-weighted images were
acquired using a 2-dimensional fast spin-echo (FSE) pulse sequence with parameters:
TR/TE = 3000/10 ms, ETL = 4, effective TE = 40ms, FOV = 25.6 x 25.6 mm 2, matrix
size = 128 x 128, slice thickness= 1 mm. Upon initial tumor detection, 2-slices from the
T2-weighted images with maximum tumor coverage (2 mm thickness) were selected for
CEST imaging. CEST images were acquired using the FSE pulse sequence (TR/TE =
7000/7 ms, ETL = 32, effective TE = 7ms, FOV = 25.6 x 25.6 mm 2, matrix size = 64 x
64, slice thickness = 2 mm) preceded by a continuous RF saturation pulse with amplitude
1.5-µT and duration 4s. A series of fifty-five CEST images were acquired at different
saturation frequencies (from 1.6 to 4.5 ppm with step size = 0.1 ppm, from 5.4 to 6.6 ppm
with step size =0.1 ppm, as well as-1000 and 1000 ppm reference images. CEST images
were acquired three times before and three times beginning immediately after drug
injection and averaged to improve signal-to-noise ratio. For B0 correction, the water
saturation shift referencing (WASSR) technique was used [27]. Linearly spaced 37-point
WASSR CEST spectra were acquired with saturation frequencies ranging from -0.6 to
0.6 ppm using the same pulse sequence except preceded by a short RF pulse (100 ms)
with low amplitude (0.2 µT). Each WASSR spectrum and CEST spectrum was
interpolated to a 1-Hz resolution. The CEST spectrum for each pixel was then frequency
shifted, using the corresponding WASSR spectrum, to account for regional B 0 variation.
A single pre- and a single post-injection CEST spectrum were created by averaging the
three CEST spectra acquired before and after drug injection, respectively. A B1 field map
was generated using an actual flip-angle imaging (AFI) pulse sequence (TR = 20 ms, TE
= 3.47 ms, echoes = 2, flip-angle = 700, FOV = 25.6 x 25.6 mm2, matrix size= 64 x 64)
[28]. The B1 variation in the CEST slice was less than 5%, and as a result no B1correction
was necessary. All CEST analyses were performed using MATLAB (Mathworks, Natick,
MA, USA). AACID values were calculated directly from the B0 corrected CEST spectra
using Equation [1] as previously described [23,24]. AACID values were calculated on a
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voxel by voxel basis directly from the CEST spectra acquired at baseline and after TPM
injection within manually defined regions of interest (ROIs) within the tumor and on the
contralateral side.

To assess the magnitude of the change in CEST signal after treatment, a contrast to noise
ratio (CNR) map was produced using Equation [2] below, where CESTBaseline represents a
CEST parameters (AACID and pH) measured before TPM treatment, CESTTPM
represents CEST parameters (AACID and pH) measured after TPM treatment, and the
background noise (

Noise)

represents the standard deviation of a CEST parameter

measured in the contralateral region before TPM treatment (N= the number of animals)

[2]

2.2.6 AACID- pH calibration: To improve interpretation of the results, pHi was
approximated from the AACID values using a linear approximation. To calibrate pHi,
average CEST spectra were obtained within tumor and contralateral tissue in vivo (N=8)
using the method described above. The measured AACID values for each tissue type
were plotted against the expected pH values in corresponding regions (pH = 7.0 in
contralateral brain tissue [29-31], pH =7.3 in tumor tissue [32-34]). The pH value
assigned to tumor ROI reflects the pH value measured in hepatoma and mammary
sarcomas in rat models using
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P-MRS. The best-fit linear relation was used to relate

AACID values to in vivo pHi.
2.2.7 Statistical Analysis: AACID and pH values were calculated at baseline and
following injection of TPM, within contralateral and tumor ROIs defined in each mouse
brain using MATLAB. The ROIs containing tumor tissue and contralateral tissue were
drawn manually based on the signal changes observed in the T2-weighted images. A
paired t-test (Microsoft Excel 2012) was used to calculate differences in mean AACID
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and pH values measured in the tumor and in contralateral ROIs before and after drug
injection. A similar comparison was made in control mice using the AACID and pH
values from the whole brain. For control animals a whole brain ROI was drawn manually
using the standard T2-weighted anatomical images.
2.3 Results
2.3.1 AACID- pH calibration
The AACID-pH calibration results are provided in Figure 1. The best-fit linear relation
given by the blue line in Figure 1 was used to relate AACID values to in vivo pHi
(Equation [3]):

Figure 1 AACID pH calibration. To relate AACID values to pH, AACID values in
contralateral ROI were assigned to pH = 7.0, and AACID values in tumor ROI were
assigned to pH = 7.3 and were fitted to linear model. The generated linear Equation was
then used to generate pH maps in experimental animals.
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2.3.2 CEST imaging in normal mouse brain tissue following TPM treatment
AACID maps from the brain of a control Nu/Nu mouse showed no change between the
baseline scan and the scan acquired one hour after TPM injection (Figure 2a and 2b). The
corresponding pH maps for the same mouse brain employing Equation [3] are also
provided (Figures 2c and 2d). There were no significant differences between the mean
(N=3) brain AACID CEST and pH values measured before and one hour after
administration of TPM (Figure 3). Figure 2e and 2f represents the AACID and pH
contrast maps employing Equation [2].

Figure 2 Representative AACID and corresponding pH maps from a healthy
NU/NU mouse brain. CEST images acquired immediately before (a) and ~75 min after
i.p. injection of 120mg/kg TPM (b).The corresponding pH distribution maps are provided
in (c) and (d). AACID and pH values were calculated from the CEST spectra acquired at
baseline and after TPM treatment using Equations 1 and 3.The AACID contrast (e) and
pH contrast (f) distribution maps showed minor variations in contrast values following
TPM administration.
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Figure 3 Summary of CEST measurements from healthy NU/NU mice (N=3). a)
Mean AACID, and b) mean pH values acquired at baseline and ~75 min after 120 mg/kg
TPM treatment in the whole brain. No significant differences were observed in AACID
and pH values calculated before and after TPM treatment. As a result the TPM induced
contrast was equal to background noise. All the error bars represent ± one standard
deviation.

2.3.3 CEST imaging of U87MG brain tissue following TPM treatment
A representative anatomical T2-weighted MR image acquired in a NU/NU mouse, 15 ± 2
days post U87MG cancer cell implantation shows typical manually defined regions of
interest (Figure 4). Average CEST spectra (B0–corrected) from one animal incorporating
all pixels within the contralateral tissue ROI (Figure 5a) and tumor tissue ROI (Figure 5b)
demonstrate clear differences in overall CEST effect as well as the CEST effect at 3.5
ppm. Pre injection spectra are shown in blue and post injection spectra are in shown in
red (Figure 5). At baseline amine protons at 2.75 ppm did not produce any notable CEST
effect in the contralateral ROI. However, amide protons resonating at 3.5 ppm generated
a relatively higher CEST effect in tumor tissue compared to tissue on the contralateral
side (Figure 5b). This higher amide CEST in the tumor ROI is attributed to several
factors including an alkaline pHi and increased protein content [35,36]. Topiramate had
no effect on amide CEST in the contralateral ROI (Figure 5a). Conversely, changes in
amide CEST effect were more pronounced in the tumor tissue ROI after topiramate
administration (Figure 5b). Specifically, the amplitude of the amide CEST peak
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decreased markedly following TPM administration. These results strongly suggest that
TPM induced acidification, as the amide proton CEST effect decreases with decreasing
pH. Quantitative AACID and pH distribution maps in one animal measured at baseline
(Figure 6a, c) and 1 hour after TPM injection (Figure 6b, d) clearly show evidence of
tumor selective acidification. Pre-injection (baseline) AACID distribution maps
consistently showed higher AACID values on the contralateral ROI and lower AACID
values within tumor ROI (Figure 6a). As expected this is reflected as higher pH values in
tumor ROIs and lower pH values in contralateral ROIs (Figure 6c). Post injection AACID
maps showed a marked increase in AACID values in the tumor ROI (Figure 6b) in this
animal, which corresponds to a decrease in tumor pHi (Figure 6d). The AACID and pH
contrast maps generated using Equation [2] are shown in Figure 6e and 6f respectively.
Figure 7 summarizes the mean AACID and pH values measured in all animals with
tumors before and one hour after TPM treatment. Average AACID values did not change
in the contralateral ROI (Figure 7a) after TPM injection. Conversely as expected in the
tumor ROI, AACID values were significantly higher (0.045) (p<0.05, N=8) after TPM
injection compared to baseline (Figure 7b). This corresponded to an average decrease of
0.12 pH units (p<0.05, N=8) after TPM injection (Figure 7d) in tumor tissue and no
significant effect on pH values in contralateral ROIs (Figure 7c). The average AACID
and pH CNR [mean CNR ± standard deviation] within tumor was: 1.86 ± 0.54 (AACID)
and 1.85 ± 0.55 (pH), while the average AACID and pH CNR [mean CNR ± standard
deviation] in contralateral tissue was: 0.12 ± 0.72 (AACID) and 0.11 ± 0.72 (pH).
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Figure 4 Standard anatomical T2-weighted MR image of a mouse brain with a U87
human Glioblastoma Multiforme tumor at day 17. The hyperintense tumor region of
interest (ROI) was manually drawn (dashed line) as was the contralateral ROI (solid line).

Figure 5 CEST spectra acquired in representative animal at baseline and ~75
minutes after administration of TPM. Average CEST spectra, from the ROI containing
contralateral tissue (a), and from the ROI containing tumor tissue (b) with error bars
equal to one standard deviation. Pre- and post- injection 6 ppm points were assigned the
same values to clearly see the relative changes in amine (2.75 ppm) and amide (3.5 ppm)
CEST effects.
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Figure 6 Representative AACID and corresponding pH maps from a NU/NU mouse
brain with tumor. CEST images acquired immediately before (a) and ~75 minutes after
i.p. injection of 120 mg/kg TPM (b). The corresponding pH distribution maps are
provided in (c) and (d). The AACID contrast map (e) and pH contrast map (f) show
changes in CEST effects following tumor selective acidification by a single dose of TPM.
Tumor regions are shown in dotted lines.
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Figure 7 Summary of the CEST parameters from NU/NU mice with U87
glioblastoma brain tumors (N=8). Mean AACID (a, b) and mean pH (c, d) values
acquired in contralateral ROI (a, c) and tumor ROI (b, d) with error bars equal to ± one
standard deviation. The mean contrast values are also shown with error bars equal to ±
one standard deviation. The mean AACID and pH values are shown at baseline (purple)
and at ~ 75 min after 120 mg/kg TPM treatment (red), along with the measured contrast
(green).
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2.4 Discussion
The purpose of this study was to investigate whether a single dose of the drug topiramate
could induce tumor selective acidification and if the decreased pH was detectable by
AACID CEST MRI. Topiramate is an anticonvulsant drug that is widely used to treat
epileptic seizures. Topiramate inhibits a wide range of carbonic anhydrases including
tumor associated (CAII, CAIX, and CAXII). These CAs contribute to the maintenance of
an alkaline intracellular pH in tumors [15]. The study herein is the first to report a
significant acute decrease in tumor tissue pH measured by AACID CEST MRI following
TPM injection.
Tumor cells have been associated with increased glycolysis and lactate production. To
counterbalance the acidic load produced, and maintain a high pHi that favors survival and
growth [19], there is increased expression of membrane transporters such as the Na+/H+
exchanger, Cl-/HCO3- exchangers, Na+/HCO3-cotransporters, H+/lactate cotransporters,
and the carbonic anhydrases CAII, CAIX and CAXII. Expression of carbonic anhydrases
has been associated with poor prognosis in various human brain tumors [17,37,38]. These
CAs play a vital role in maintaining an alkaline pHi, which is permissive of cell
proliferation and evasion of apoptosis. In contrast, it has previously been hypothesized
that intracellular acidification could enhance apoptosis to control tumor growth [39]. For
example, acidification of the intracellular compartment of melanoma xenografts has been
shown to enhance the cytotoxic effect of the weakly acidic chemotherapy drug Melphalan
[40]. Also, the CA inhibitor acetazolamide has shown to induce apoptosis in human
cervical and renal carcinoma cell lines, in vitro, by inhibition of CAIX[41].In addition,
the intracellular acidification of a mammary carcinoma cell line by the Na+/H+ inhibitor
amiloride increased the effect of hyperthermia treatment [42,43]. Finally, combined
silencing of CAIX and CAXII in fibroblasts decreased pHi by 0.2 units, and tumor
volume by 85% [15].

All of these studies suggest that acidification of the tumor

environment could have therapeutic applications in cancer management. The
sulphonamide derivative, TPM, binds to the zinc (Zn 2+) ion of the carbonic anhydrases,
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thus inhibiting CO2 hydration and disturbing pH regulation in tumors[12].A previous
study using topiramate to treat Lewis lung carcinoma showed an inhibitory effect on
tumor metastasis, potentially due to inhibition of AQP1[26].
Our group has previously demonstrated tumor selective acidification induced by a single
dose of the drug Lonidamine (LND) using AACID CEST MRI. A significant increase in
AACID value (0.15 units) was evident one hour after LND administration. This
acidification was likely a result of decreased glycolysis and decreased lactate efflux after
LND injection. In the current study the increase in AACID value (0.045 units) was
considerably less than the LND induced change. One potential explanation for this
difference is that LND targets the Na +/H+ antiport which may be a more efficient
regulator of pHi under hypoxic conditions compared to the transport of bicarbonate ions
formed during the catalytic activity of CA through Cl -/HCO3- transporters [44-46].
It should be noted that the pH values presented in the current study were estimated based
on a calibration using pH values previously published in the brain. Some assumptions
were made including: 1) the contralateral tissue in the tumor bearing animals was normal
with pHi 7.0 [30,31] and 2) the pHi of tumor tissue was 7.3 [32-34].To develop the pH
relation to AACID, AACID CEST values in glioma tumors and normal brain tissue
obtained in the experimental animals were plotted against the published pH values in
tumor tissue and normal tissue calculated by
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P MRS. Further work is needed to

calibrate the AACID- pH Equation in glioma tumors. The variability observed in the
AACID and pH values (Figure 7b, d) within the tumor ROI may be due to biological
variation in the animals, variation in the development of tumor vasculature in different
animals, and the time of the scan (range from 13 days to17 days post cell implantation).
The AACID and pH maps could also be improved in the future by increasing the signal to
noise ratio of the acquired CEST images. Interestingly, we observed an increase in
contrast in some regions of the contralateral brain (top and bottom left) following TPM
injection (Figure 6). The phenomenon underlying this change may be related to structural
and physiological changes within the tissue induced by pressure from the tumor.
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Most of the studies on Topiramate and other CAIs are focused on epilepsy and other
physiological conditions while only limited data are available for their use in cancer.
Acetazolamide is one of the most studied CAI in cancer research and may also decrease
tumor pHi and delay tumor growth [20,47]. The results of the current study are also
consistent with Leniger et.al., who has suggested that changes in pHi of hippocampal
neurons can be caused by inhibition of CAs [48].
The study presented here used a small sample size; therefore this preliminary work
should be repeated with more animals. The dose studied here (120mg/kg) was chosen
based on the study by Bing et. al.,[26] as the rate of inhibition of tumor metastasis was
highest at this dose. ATPM dose as high as 400mg/day has been safely used in adults in
the treatment of epilepsy. The main side effect associated with the TPM treatment is
acute confusion and metabolic acidosis at this dose [49]. Future work is needed to find
the optimal TPM dose that produces the highest CEST effects in tumors.

Future

longitudinal studies are also required to evaluate the effect of long-term TPM treatment
on tumor progression. Recently, many studies have shown the potential of different CAIs
to control tumor growth and metastasis [50,51]. Also, the risk of having epileptic seizures
in tumor patients is high, therefore investigating the use of antiepileptic drugs in cancer
treatment has high translational potential [52]. Finally, other CA inhibitors should be
investigated to differentiate, detect, grade and predict the outcome of possible anticancer
therapies.
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3 Conclusions and Future Directions
In this section, limitations of the study and a brief summary of relevant findings of
Chapter 2 are considered. In addition, some implications and future directions are
discussed.
3.1 Limitations
There are several limitations to the current work that should be considered.
i) In the treatment of epileptic seizures, topiramate (400 mg/d) is used orally in humans.
In this thesis we have used intraperitoneal (i.p.) topiramate at a dose of 120 mg/kg, which
is comparatively higher than the dose used in humans. Also, although topiramate is
widely used in the treatment of epilepsy there is no injectable product. However in one
investigational study, it has been shown that the bioavailability of the intravenous
formulation and the oral formulation is equivalent and that the intravenous formulation is
well tolerated in healthy adults and adults with epilepsy, and that a single dose of
intravenous topiramate can be safely administered [1-3]. However, the study presented in
this thesis was not designed to optimize the topiramate dose used in humans for cancer
detection.
ii) The pH values presented in this study were approximated. The AACID-pH
relationship used in this study was not developed using an independent pH calibration.
Rather, it was developed by equating the average AACID values measured in tumors and
contralateral tissue, to published pH values from these same tissue measured using
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P-

MRS and assuming a linear dependence.
iii) The experiment was not designed to measure the long-term effect of topiramate on
tumors. Therefore we cannot judge whether topiramate can play a role in tumor
management or could be a part of the treatment regime.
iv) There was great variability in the effect of topiramate on pHi in different animals.
This variability was independent of the size of the tumor and might be related to the
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expected heterogeneous vasculature in these tumors; although, this effect was not verified
in this study.
3.2 Conclusions
Cancer affects millions of people world-wide [4]and many malignant forms of cancer are
difficult to treat with the traditional available treatment options. The concept of exploring
the use of carbonic anhydrase inhibitors in cancer treatment is increasing, in part due to
their effect on pH regulation in tumors [5]. In light of several excellent reviews, we
attempted to measure pH changes induced by a single dose of the CAI topiramate using
the AACID CEST MRI technique [6,7]. In malignant glioblastoma tumors implanted in
immune–compromised mice, the results presented indicated that topiramate decreased
pHi by 0.12 units within 75 min after administration. On average we did not observe any
change in pHi in the contralateral brain regions of mice with tumors or in the brains of
healthy mice. This finding is very exciting considering that intracellular acidification of
the tumor intracellular space could improve the efficacy of chemotherapy as well as
hyperthermia treatment [8,9].
3.3 Future Directions
This thesis examined the effect of the carbonic anhydrase inhibitor, Topiramate, on tumor
pHi. pH is elevated in tumors and is an important contributor to tumor cell
proliferation[10]. In contrast, acidification of the tumor intracellular space increases the
rate of apoptosis as well as induces tumor growth delay. Many other carbonic anhydrase
inhibitors have shown promise in inhibiting tumor associated carbonic anhydrases.
Therefore a logical extension of this work would be to evaluate the effect of these CAI on
tumor pHi and optimize the drug that causes the greatest decrease in pHi with therapeutic
dosages. Also, it will be interesting to design longitudinal experiments to observe the
effects of Topiramate on tumor growth and optimize the dose for maximum growth delay
as well as treating tumors with different combination of CAI to see if they work
synergistically. A well-established antiepileptic drug Valporate was proposed to have
antitumor activity and has been shown to decrease tumor growth and metastasis [11].
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Therefore we should examine the combined effects of drugs that have different targets to
control tumor growth.
Reports on the expression of CA II in glioblastoma are scarce but have indicated that
many malignant cell lines express CA II at low levels. [12-14]. In contrast, expression of
CAIX and CAXII is elevated in different tumor lines including glioblastoma [12,15-17].
Topiramate is a potent inhibitor of CAII and moderate inhibitor of CAIX. CAIX has a
catalytic performance rate similar to CAII. Knockdown of CAIX increased the rate of
apoptotic cell death after radiation and temozolomide treatment [17].

In addition,

inhibition of the CAIX carbonic anhydrase decreased the rate of metastasis in a mouse
model of breast tumor [17,18]. Therefore it would be of interest to compare the effects of
tumor specific CAIX inhibitors and CAII inhibitors on tumor pHi.
Another extension of this thesis would be to measure pHe along with pHi to monitor the
effect on extracellular pH, as it is the pH gradient across the plasma membrane that
impacts the efficacy of chemotherapy drugs. This simultaneous measurement of pHi and
pHe may aid to design the most effective and personalized treatment regime.
The results from this study indicate the potential value of carbonic anhydrase inhibitors in
tumor acidification and hopefully will stimulate future experiments to expand the role of
such drugs in cancer treatment.
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PI Name: Bartha, Robert
AUP Title: Development Of Novel Targeted MRI Contrast Agents
Approval Date: 04/29/2015
Official Notice of Animal Use Subcommittee (AUS) Approval: Your new Animal Use
Protocol (AUP) entitled "Development of Novel Targeted MRI Contrast Agents" has
been APPROVED by the Animal Use Subcommittee of the University Council on
Animal Care. This approval, although valid for four years, is subject to annual Protocol
Renewal.2015-005: 1
1. This AUP number must be indicated when ordering animals for this project.
2. Animals for other projects may not be ordered under this AUP number.
3. Purchases of animals other than through this system must be cleared
through the ACVS office. Health certificates will be required.
The holder of this Animal Use Protocol is responsible to ensure that all associated safety
components (biosafety, radiation safety, general laboratory safety) comply with
institutional safety standards and have received all necessary approvals. Please consult
directly with your institutional safety officers.
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